<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39398093</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2616-163X</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Ghana medical journal</Title><ISOAbbreviation>Ghana Med J</ISOAbbreviation></Journal><ArticleTitle>Management and associated outcomes of COVID-19 infection among Ghanaian autoimmune rheumatic disease patients.</ArticleTitle><Pagination><StartPage>184</StartPage><EndPage>191</EndPage><MedlinePgn>184-191</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4314/gmj.v58i3.2</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">This study assessed the prevalence of infection, management strategies and associated disease outcomes of COVID-19 among Autoimmune Rheumatic Disease (AIRD) patients in a teaching hospital in Ghana.</AbstractText><AbstractText Label="DESIGN" NlmCategory="UNASSIGNED">This was a retrospective cross-sectional study.</AbstractText><AbstractText Label="SETTING" NlmCategory="UNASSIGNED">Rheumatology Unit, Korle Bu Teaching Hospital.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="UNASSIGNED">Autoimmune Rheumatic Disease patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Thirty-one (31) out of approximately 1700 AIRD patients in the unit tested positive for COVID-19, registering a COVID-19 prevalence of 1.82%. The majority, 25(80.6%), were females with a mean ± SD age of 41.7 ± 12.8 years. Systemic lupus erythematosus was the most affected autoimmune rheumatic condition, reporting fever as the commonest COVID-19-related symptom. Most participants, 22(71%), were managed by the "self-isolation"/home management" strategy. In comparison, 7(22.5%) were monitored at the hospital, with both strategies having resulted in complete recovery. The remaining 2(6.5%) patients who managed under "intensive care unit" strategy resulted in mortality.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">These findings highlight the relatively low frequency of COVID-19 infection among AIRD patients, the encouraging recovery, and the low severe disease rates observed within this cohort. Additionally, the outcome of self-isolation and home management strategies underscore the importance of personalised approaches to COVID-19 management in this population.</AbstractText><AbstractText Label="FUNDING" NlmCategory="UNASSIGNED"><b>None</b>.</AbstractText><CopyrightInformation>Copyright © The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dey</LastName><ForeName>Dzifa</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine and Therapeutics, University of Ghana Medical School, Legon, Accra, Ghana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Medicine and Therapeutics, Korle-Bu Teaching Hospital, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katso</LastName><ForeName>Bright</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Medicine and Therapeutics, Korle-Bu Teaching Hospital, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyame</LastName><ForeName>Derrick</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine and Therapeutics, University of Ghana Medical School, Legon, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Issaka</LastName><ForeName>Saudatu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Medicine and Therapeutics, Korle-Bu Teaching Hospital, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adjei</LastName><ForeName>Partrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine and Therapeutics, University of Ghana Medical School, Legon, Accra, Ghana.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ghana</Country><MedlineTA>Ghana Med J</MedlineTA><NlmUniqueID>0073210</NlmUniqueID><ISSNLinking>0016-9560</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005869" MajorTopicYN="N" Type="Geographic">Ghana</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012216" MajorTopicYN="Y">Rheumatic Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoimmune Rheumatic Disease (AIRD)</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Management</Keyword><Keyword MajorTopicYN="N">Outcome</Keyword><Keyword MajorTopicYN="N">Self-isolation</Keyword></KeywordList><CoiStatement>Conflict of interest: None declared</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39398093</ArticleId><ArticleId IdType="pmc">PMC11465720</ArticleId><ArticleId IdType="doi">10.4314/gmj.v58i3.2</ArticleId><ArticleId IdType="pii">jGMJ.v58.i3.pg184</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andersen K G, Rambaut A, Lipkin W I, Holmes E C, Garry R F. The proximal origin of SARS-CoV-2. Nature Medicine. 2020;26(4):450–452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095063</ArticleId><ArticleId IdType="pubmed">32284615</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P, Yang X L, Wang X G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenu E, Odikro MA, Malm KL, Asiedu-Bekoe F, Noora CL, Frimpong JA, Calys-Tagoe B, Koram KA. Epidemiology of COVID-19 outbreak in Ghana, 2020. Ghana Med J. 2020;54(4 Suppl):5–15. doi: 10.4314/gmj.v54i4s.3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8087358</ArticleId><ArticleId IdType="pubmed">33976436</ArticleId></ArticleIdList></Reference><Reference><Citation>Ofori SK, Schwind JS, Sullivan KL, Cowling BJ, Chowell G, Fung IC. Transmission Dynamics of COVID-19 in Ghana and the Impact of Public Health Interventions. Am J Trop Med Hyg. 2022;107(1):175–179. doi: 10.4269/ajtmh.21-0718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9294683</ArticleId><ArticleId IdType="pubmed">35605636</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenu E, Frimpong JA, Koram KA. Responding to the COVID-19 pandemic in Ghana. Ghana Med J. 2020;54(2):72–73. doi: 10.4314/gmj.v54i2.1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7829051</ArticleId><ArticleId IdType="pubmed">33536675</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibiri H, Zankawah S, Prah D. Coronavirus diseases 2019 (COVID-19) response: highlights of Ghana's scientific and technological innovativeness and breakthroughs. Ethics Med Public Health. 2020;14:100537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7250762</ArticleId><ArticleId IdType="pubmed">32835055</ArticleId></ArticleIdList></Reference><Reference><Citation>Druyan A, Lidar M, Brodavka M, Levy I, Barzilai A, Pavlotsky F. The risk for severe COVID-19 in patients with autoimmune and inflammatory diseases: First wave lessons. Dermatologic Therapy. 2021;34:e14627. doi: 10.1111/dth.14627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dth.14627</ArticleId><ArticleId IdType="pmc">PMC7883029</ArticleId><ArticleId IdType="pubmed">33277764</ArticleId></ArticleIdList></Reference><Reference><Citation>Kluge HHP, Wickramasinghe K, Rippin HL, Mendes R, Peters DH, Kontsevaya A, Breda J. Prevention and control of non-communicable diseases in the COVID-19 response. Lancet. 2020;395:1678–1680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7211494</ArticleId><ArticleId IdType="pubmed">32401713</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi G, Wang H, Guo Y, Peng C, Zhang C, Chen T, He J, Jin Z. Clinical outcomes of COVID-19 patients with rheumatic diseases: a retrospective cohort study and synthesis analysis in Wuhan, China. Clinical Rheumatology. 2022;41(6):1899–1910.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8853197</ArticleId><ArticleId IdType="pubmed">35171364</ArticleId></ArticleIdList></Reference><Reference><Citation>Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmunity reviews. 2020;19(5):102523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102591</ArticleId><ArticleId IdType="pubmed">32205186</ArticleId></ArticleIdList></Reference><Reference><Citation>Pope JE. What Does the COVID-19 Pandemic Mean for Rheumatology Patients? Curr Treat Options in Rheum. 2020;6:71–74. doi: 10.1007/s40674-020-00145-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40674-020-00145-y</ArticleId><ArticleId IdType="pmc">PMC7191545</ArticleId><ArticleId IdType="pubmed">32355607</ArticleId></ArticleIdList></Reference><Reference><Citation>Maddur MS, Vani J, Lacroix-Desmazes S, Kaveri S, Bayry J. Autoimmunity as a predisposition for infectious diseases. PLoS Pathog. 2012;6:e1001077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2973828</ArticleId><ArticleId IdType="pubmed">21079687</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansarin K, Taghizadieh A, Safiri S, et al. COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs. Ann Rheum Dis. 2020;0(0):annrheumdis-2020-218737.</Citation><ArticleIdList><ArticleId IdType="pubmed">32759256</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C, Yi Z, Cai R, Chen R, Thong BY, Mu R. Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data. Autoimmun Rev. 2021;20(4):102778. doi: 10.1016/j.autrev.2021.102778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7889462</ArticleId><ArticleId IdType="pubmed">33609804</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: A systematic review and meta-analysis. Ann Rheum Dis. 2020. pp. 1–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">33051220</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladani AP, Loganathan M, Danve A. Managing rheumatic diseases during COVID-19. Clin Rheumatol. 2020 Nov;39(11):3245–3254. doi: 10.1007/s10067-020-05387-8. Epub. 2020. PMID: 32895747; PMCID: PMC7476772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7476772</ArticleId><ArticleId IdType="pubmed">32895747</ArticleId></ArticleIdList></Reference><Reference><Citation>Akintayo RO, Akpabio A, Kalla A, et al. COVID-19 and the practice of rheumatology in Africa: significant changes to services from the shockwave of a pandemic. Ann Rheum Dis. 2020;0(0):annrheumdis-2020-218273.</Citation><ArticleIdList><ArticleId IdType="pubmed">32611599</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornet A, Andersen J, Tani C, Mosca M. Hydroxychloroquine availability during COVID-19 crisis and its effect on patient anxiety. Lupus Sci Med. 2021;8(1):e000496. doi: 10.1136/lupus-2021-000496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8057069</ArticleId><ArticleId IdType="pubmed">33875571</ArticleId></ArticleIdList></Reference><Reference><Citation>American College of Rheumatology, author. Patients reported international hydroxychloroquine shortages due to COVID-19. ScienceDaily. 2021.  Retrieved February 4, 2024 from  www.sciencedaily.com/releases/2020/11/201106103103.htm.</Citation></Reference><Reference><Citation>Republic of Ghana Ministry of Health, author. Provisional Standard Treatment Guidelines for Novel Coronavirus Infection: COVID-19 Guidelines for Ghana.  Available online:  https://www.moh.gov.gh/wp-content/uploads/2016/02/COVID-19-STG-JUNE-2020-1.pdf.</Citation></Reference><Reference><Citation>Favalli Ennio Giulio, Maioli Gabriella, Biggioggero Martina, Caporali Roberto. Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic. Expert Review of Clinical Immunology. 2021;17:6. 561–571. DOI: 10.1080/1744666X.2021.1908887.</Citation><ArticleIdList><ArticleId IdType="pubmed">33787418</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala Gutiérrez MDM, Rubio-Rivas M, Romero Gómez C, et al. Autoimmune Diseases and COVID-19 as Risk Factors for Poor Outcomes: Data on 13,940 Hospitalised Patients from the Spanish Nationwide SEMI-COVID-19 Registry. J. Clin. Med. 2021;10:1844. doi: 10.3390/jcm10091844.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10091844</ArticleId><ArticleId IdType="pmc">PMC8123043</ArticleId><ArticleId IdType="pubmed">33922777</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EH, Sena AG, Prats-Uribe A, et al. COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries. Rheumatology (Oxford) 2021;9(60):SI37–SI50. (SI), doi: 10.1093/rheumatology/keab250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7989171</ArticleId><ArticleId IdType="pubmed">33725121</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155–162. doi: 10.1097/BOR.0000000000000776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7880581</ArticleId><ArticleId IdType="pubmed">33332890</ArticleId></ArticleIdList></Reference><Reference><Citation>Grainger R, Kim AHJ, Conway R, Yazdany J, Robinson PC. COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. Nat Rev Rheumatol. 2022;18(4):191–204. doi: 10.1038/s41584-022-00755-x.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8874732</ArticleId><ArticleId IdType="pubmed">35217850</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR. European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 Sep;71(9):1400–1412. 2019, doi: 10.1002/art.40930. Epub.2019. PMID: 31385462; PMCID: PMC6827566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6827566</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId></ArticleIdList></Reference><Reference><Citation>Kay Jonathan, Katherine S. Upchurch, ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology. 2012;5(6):vi5–vi9. doi: 10.1093/rheumatology/kes279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kes279</ArticleId><ArticleId IdType="pubmed">23221588</ArticleId></ArticleIdList></Reference><Reference><Citation>Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 2013;52:53–61. doi: 10.1093/rheumatology/kes305.</Citation><ArticleIdList><ArticleId IdType="pubmed">23192911</ArticleId></ArticleIdList></Reference><Reference><Citation>Falagas ME, Manta KG, Betsi GI, Pappas G. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol. 2007;26:663–670. doi: 10.1007/s10067-006-0441-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17186117</ArticleId></ArticleIdList></Reference><Reference><Citation>Gheita TA, Salem MN, Eesa NN, et al. Rheumatologists' practice during the Coronavirus disease 2019 (COVID-19) pandemic: a survey in Egypt. Rheumatol Int [Internet] 2020;40(10):1599–1611. doi: 10.1007/s00296-020-04655-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-020-04655-9</ArticleId><ArticleId IdType="pmc">PMC7380140</ArticleId><ArticleId IdType="pubmed">32710198</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri C, Giuggioli D, Raimondo V, et al. COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series. Clin Rheumatol. 2020;39(11):3195–3204. doi: 10.1007/s10067-020-05334-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7450255</ArticleId><ArticleId IdType="pubmed">32852623</ArticleId></ArticleIdList></Reference><Reference><Citation>Felten R, Scherlinger M, Guffroy A, et al. Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France. Arthritis Research &amp; Therapy. 2021;23:1–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8276223</ArticleId><ArticleId IdType="pubmed">34256812</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyrich KL, Machado PM. Rheumatic disease and COVID-19: epidemiology and outcomes. Nature Reviews Rheumatology. 2021;17(2):71–72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7747184</ArticleId><ArticleId IdType="pubmed">33339986</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Silva KM, Wallace ZS. COVID-19 and rheumatoid arthritis. Curr Opin Rheumatol. 2021;33(3):255–261. doi: 10.1097/BOR.0000000000000786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8784188</ArticleId><ArticleId IdType="pubmed">33625043</ArticleId></ArticleIdList></Reference><Reference><Citation>Sefah IA, Sarkodie SA, Pichierri G, Schellack N, Godman B. Assessing the Clinical Characteristics and Management of COVID-19 among Pediatric Patients in Ghana: Findings and Implications. Antibiotics. 2023;12(2):283. doi: 10.3390/antibiotics12020283.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics12020283</ArticleId><ArticleId IdType="pmc">PMC9952352</ArticleId><ArticleId IdType="pubmed">36830194</ArticleId></ArticleIdList></Reference><Reference><Citation>Yawson AE, Oduro-Mensah E, Tetteh J, Adomako I, Adjei-Mensah E, Owoo C, Yawson AO, Oliver-Commey JA, Puplampu P, Samba A, Lartey M. Clinical features of COVID-19 in Ghana: symptomatology, illness severity and comorbid non-communicable diseases. Ghana Medical Journal. 2020;54(4s):23–32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8087366</ArticleId><ArticleId IdType="pubmed">33976438</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf VL, Ryan MJ. Autoimmune Disease-Associated Hypertension. Curr Hypertens Rep. 2019 Feb 2;21(1):10. doi: 10.1007/s11906-019-0914-2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6394456</ArticleId><ArticleId IdType="pubmed">30712132</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanyaolu A, Okorie C, Marinkovic A, et al. Comorbidity and its Impact on Patients with COVID-19. Compr. Clin. Med. 2020. pp. 1–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314621</ArticleId><ArticleId IdType="pubmed">32838147</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, Iotti G. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. Jama. 2020;323(16):1574–1581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7136855</ArticleId><ArticleId IdType="pubmed">32250385</ArticleId></ArticleIdList></Reference><Reference><Citation>Grainger R, Kim AHJ, Conway R, et al. COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. Nat Rev Rheumatol. 2022;18:191–204. doi: 10.1038/s41584-022-00755.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-022-00755</ArticleId><ArticleId IdType="pmc">PMC8874732</ArticleId><ArticleId IdType="pubmed">35217850</ArticleId></ArticleIdList></Reference><Reference><Citation>Landewé R B, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann. Rheum. Dis. 2020;79:851–858.</Citation><ArticleIdList><ArticleId IdType="pubmed">32503854</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikuls T R, et al. American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 3. Arthritis Rheumatol. 2021;73:e1–e12.</Citation><ArticleIdList><ArticleId IdType="pubmed">33277981</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimised Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Clin. Infect. Dis. 2020;71:732–739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108130</ArticleId><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Z, Liu J, Shi D, et al. Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels. Int J Biol Sci. 2020;16(13):2382–2391. doi: 10.7150/ijbs.47652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7378642</ArticleId><ArticleId IdType="pubmed">32760206</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2021;93(1):250–256. doi: 10.1002/jmv.26232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361342</ArticleId><ArticleId IdType="pubmed">32592501</ArticleId></ArticleIdList></Reference><Reference><Citation>Favalli EG, Monti S, Ingegnoli F, Balduzzi S, Caporali R, Montecucco C. Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data? Arthritis Rheumatol. 2020;72(10):1600–1606. doi: 10.1002/art.41388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7300434</ArticleId><ArticleId IdType="pubmed">32506699</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>